Skip to content

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01238575
Enrollment
62
Registered
2010-11-10
Start date
2011-12-31
Completion date
2014-03-31
Last updated
2020-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pervasive Development Disorders

Keywords

Pervasive Developmental Disorders, PDD, PDD-NOS, Autistic Disorder, Autism, Asperger's Disorder, Hyperactivity, Attention Deficit Hyperactivity Disorder, ADHD, Medication, Drug, Guanfacine, Intuniv, Placebo, Methylphenidate

Brief summary

The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself or in combination with methylphenidate (also known as Ritalin) is helpful for treating hyperactivity in children and adolescents with a Pervasive Developmental Disorders (PDDs).

Detailed description

Pervasive Developmental Disorders (PDDs) are a group of conditions that includes Autistic Disorder, Asperger's disorder and so called Pervasive Developmental Disorder - Not Otherwise Specified. Children with PDD show delays in speech and language and reduced social interaction. Some children with PDD have also have problems with overactivity, impulsiveness and distractability. These behaviors are seen in children with Attention Deficit Hyperactivity Disorder (ADHD). Extended release guanfacine (Intuniv) is FDA-approved for the treatment of children with ADHD. The purpose of this study is to evaluate whether Intuniv is an effective treatment for ADHD symptoms in children with PDD. This study has four parts: an 8-week double-blind trial, an 8-week blinded extension phase (for positive responders only), an 8-week open-label trial, and a 4-week add-on study. Following confirmation of eligibility, participants will be randomly assigned to receive either guanfacine or placebo in the 8-week double-blind trial. Children who show improvement after 8 weeks of treatment will continue on their assigned treatment for an additional 8 weeks (blinded extension phase). Children who show partial improvement with guanfacine will be offered 4 weeks of treatment with guanfacine plus methylphenidate (add-on study). Children who show no improvement on placebo will be offered 8 weeks of treatment with guanfacine (open-label trial). Children who show no improvement on guanfacine will exit the study. Side effects and treatment response will be assessed at regularly scheduled visits. The study protocol was formally revised with the Yale University IRB in May 2013 to address an early close to enrollment due to a reduction in funding. The original anticipated enrollment numbers of 112 subjects was reduced to 60 subjects. The study statistician was consulted prior to enrollment closure to address any issues related to statistical power and the adjustments made to the final statiscal analysis plan.

Interventions

OTHERplacebo

Administered for up to 8 weeks.

DRUGextended-release guanfacine

1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks

Sponsors

Emory University
CollaboratorOTHER
Massachusetts General Hospital
CollaboratorOTHER
Seattle Children's Hospital
CollaboratorOTHER
University of California, Los Angeles
CollaboratorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Years to 14 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of PDD (PDD-NOS, Asperger's Disorder, Autistic Disorder) * Hyperactivity * Between ages 5 years 0 months and 13 years 11 months. * Weight \>/= 15 kg (33 lb) * A mental age of at least 18 months

Exclusion criteria

* Prior failed treatment with an adequate trial of guanfacine in the last 2 years * Concurrent treatment with another psychoactive medication

Design outcomes

Primary

MeasureTime frameDescription
Aberrant Behavior Checklist Hyperactivity SubscaleWeek 8The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48.

Secondary

MeasureTime frameDescription
Aberrant Behavior Checklist Irritability Subscale8 weeksThe Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. It is a 58 item checklist which takes about 10 - 15 minutes to complete. There are five subscales: a) Irritability and Agitation b) Lethargy and Social Withdrawal c) Stereotypic Behavior d) Hyperactivity and Noncompliance and e) Inappropriate Speech. The higher the number of items (score), the greater the amount of symptoms. Scores can range from 0 to 45.
Aberrant Behavior Checklist Social Withdrawal Subscale8 weeksThe Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 48.
Aberrant Behavior Checklist Sterotypy Subscale8 weeksThe Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 21.
ADHD Rating Scale - TotalWeek 8The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. The total score can range from 0 to 54, with a higher score indicating greater severity.
ADHD Rating Scale - Inattention Subscale8 weeksThe ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity.
ADHD Rating Scale - Hyperactivity Subscale8 weeksThe ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring,with a higher score indicating greater severity.
Aberrant Behavior Checklist Hyperactivity SubscaleBaselineThe Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48.
Aberrant Behavior Checklist Inappropriate Speech Subscale8 weeksThe Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 12.

Countries

United States

Participant flow

Pre-assignment details

81 total patients screened. 13 ineligible. 6 Declined

Participants by arm

ArmCount
Extended-release Guanfacine
extended-release guanfacine: 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
30
Inactive Placebo
placebo: Administered for up to 8 weeks.
32
Total62

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event20
Overall StudyLack of Efficacy24

Baseline characteristics

CharacteristicInactive PlaceboTotalExtended-release Guanfacine
Age, Continuous8.39 years
STANDARD_DEVIATION 2.23
8.4 years
STANDARD_DEVIATION 2.25
8.44 years
STANDARD_DEVIATION 2.28
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants5 Participants4 Participants
Race (NIH/OMB)
Black or African American
4 Participants11 Participants7 Participants
Race (NIH/OMB)
More than one race
3 Participants4 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants2 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
23 Participants40 Participants17 Participants
Sex: Female, Male
Female
5 Participants9 Participants4 Participants
Sex: Female, Male
Male
27 Participants53 Participants26 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
30 / 3025 / 32
serious
Total, serious adverse events
1 / 300 / 32

Outcome results

Primary

Aberrant Behavior Checklist Hyperactivity Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48.

Time frame: Week 8

ArmMeasureValue (LEAST_SQUARES_MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Hyperactivity Subscale19.3 units on a scale
Inactive PlaceboAberrant Behavior Checklist Hyperactivity Subscale29.7 units on a scale
Secondary

Aberrant Behavior Checklist Hyperactivity Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48.

Time frame: Baseline

ArmMeasureValue (MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Hyperactivity Subscale34.4 units on a scale
Inactive PlaceboAberrant Behavior Checklist Hyperactivity Subscale34.25 units on a scale
Secondary

Aberrant Behavior Checklist Inappropriate Speech Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 12.

Time frame: 8 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Inappropriate Speech Subscale4.2 units on a scale
Inactive PlaceboAberrant Behavior Checklist Inappropriate Speech Subscale5.99 units on a scale
Secondary

Aberrant Behavior Checklist Inappropriate Speech Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 12.

Time frame: Baseline

ArmMeasureValue (MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Inappropriate Speech Subscale6.33 units on a scale
Inactive PlaceboAberrant Behavior Checklist Inappropriate Speech Subscale6.84 units on a scale
Secondary

Aberrant Behavior Checklist Irritability Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. It is a 58 item checklist which takes about 10 - 15 minutes to complete. There are five subscales: a) Irritability and Agitation b) Lethargy and Social Withdrawal c) Stereotypic Behavior d) Hyperactivity and Noncompliance and e) Inappropriate Speech. The higher the number of items (score), the greater the amount of symptoms. Scores can range from 0 to 45.

Time frame: 8 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Irritability Subscale13.5 units on a scale
Inactive PlaceboAberrant Behavior Checklist Irritability Subscale16.1 units on a scale
Secondary

Aberrant Behavior Checklist Irritability Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. Scores for this subscale can range from 0 to 45.

Time frame: Baseline

ArmMeasureValue (MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Irritability Subscale20.3 units on a scale
Inactive PlaceboAberrant Behavior Checklist Irritability Subscale18.06 units on a scale
Secondary

Aberrant Behavior Checklist Social Withdrawal Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 48.

Time frame: Baseline

ArmMeasureValue (MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Social Withdrawal Subscale13.6 units on a scale
Inactive PlaceboAberrant Behavior Checklist Social Withdrawal Subscale12.06 units on a scale
Secondary

Aberrant Behavior Checklist Social Withdrawal Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 48.

Time frame: 8 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Social Withdrawal Subscale9.8 units on a scale
Inactive PlaceboAberrant Behavior Checklist Social Withdrawal Subscale8.6 units on a scale
Secondary

Aberrant Behavior Checklist Sterotypy Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 21.

Time frame: 8 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Sterotypy Subscale3.6 units on a scale
Inactive PlaceboAberrant Behavior Checklist Sterotypy Subscale5.9 units on a scale
Secondary

Aberrant Behavior Checklist Sterotypy Subscale

The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 21.

Time frame: Baseline

ArmMeasureValue (MEAN)
Extended-release GuanfacineAberrant Behavior Checklist Sterotypy Subscale8.53 units on a scale
Inactive PlaceboAberrant Behavior Checklist Sterotypy Subscale9.31 units on a scale
Secondary

ADHD Rating Scale - Hyperactivity Subscale

The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring,with a higher score indicating greater severity.

Time frame: 8 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
Extended-release GuanfacineADHD Rating Scale - Hyperactivity Subscale10.6 units on a scale
Inactive PlaceboADHD Rating Scale - Hyperactivity Subscale18.7 units on a scale
Secondary

ADHD Rating Scale - Hyperactivity Subscale

The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity.

Time frame: Baseline

ArmMeasureValue (MEAN)
Extended-release GuanfacineADHD Rating Scale - Hyperactivity Subscale19.00 units on a scale
Inactive PlaceboADHD Rating Scale - Hyperactivity Subscale19.5 units on a scale
Secondary

ADHD Rating Scale - Inattention Subscale

The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity.

Time frame: 8 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
Extended-release GuanfacineADHD Rating Scale - Inattention Subscale14.7 units on a scale
Inactive PlaceboADHD Rating Scale - Inattention Subscale19.5 units on a scale
Secondary

ADHD Rating Scale - Inattention Subscale

The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity.

Time frame: Baseline

ArmMeasureValue (MEAN)
Extended-release GuanfacineADHD Rating Scale - Inattention Subscale20.53 units on a scale
Inactive PlaceboADHD Rating Scale - Inattention Subscale20.41 units on a scale
Secondary

ADHD Rating Scale - Total

The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. The total score can range from 0 to 54, with a higher score indicating greater severity.

Time frame: Week 8

ArmMeasureValue (LEAST_SQUARES_MEAN)
Extended-release GuanfacineADHD Rating Scale - Total25.2 units on a scale
Inactive PlaceboADHD Rating Scale - Total38.0 units on a scale
Secondary

ADHD Rating Scale - Total

The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. The total score can range from 0 to 54, with a higher score indicating greater severity.

Time frame: Baseline

ArmMeasureValue (MEAN)
Extended-release GuanfacineADHD Rating Scale - Total39.53 units on a scale
Inactive PlaceboADHD Rating Scale - Total39.91 units on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026